Business Wire

MAXON Announces Cinema 4D Release 19

31.7.2017 15:03 | Business Wire

Jaa

Ahead of the SIGGRAPH 2017 conference, MAXON today announced Cinema 4D Release 19 (R19). This next generation of MAXON’s professional 3D application delivers both great tools and enhancements artists can put to use immediately and provides a peek into the foundations for the future.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170731005012/en/

Powerful developments have been made to viewport performance, a new Sound Effector and additional features for Voronoi Fracturing have been added to the MoGraph toolset, a new Spherical Camera introduced, the integration of AMD’s ProRender technology and more. Designed to serve individual artists as well as large studio environments, Release 19 offers a fast, easy, stable and streamlined workflow to meet today’s challenges in the content creation markets: especially general design, motion graphics, VFX, VR/AR and all types of visualization.

[NOTE: MAXON will debut Cinema 4D R19 at the upcoming SIGGRAPH 2017 convention July 30 – August 3, in Los Angeles, Booth #701.]

With Cinema 4D Release 19, MAXON also introduces a number of re-engineered foundational technologies, which the company will continue to develop and bring to maturity in future versions. These include core software modernization efforts, a new modeling core, deeply-integrated GPU Rendering for Windows and Mac, and OpenGL capabilities in BodyPaint 3D, MAXON’s professional paint and texturing toolset.

“For more than two decades MAXON has been dedicated to delivering 3D graphics solutions with rock-solid stability, outstanding ease of use, a fast workflow and cross-platform capability,“ says Harald Egel, managing partner at MAXON Computer GmbH. “Cinema 4D Release 19 expands on those core values with outstanding new features and a first look at foundations for the future.”

Complete feature set in Cinema 4D Release R19

Pricing, Availability / Upgrade Path
Cinema 4D Release 19 is scheduled to ship September, 2017.
Pricing and Distribution Information
Recommended System Requirements
Available for both Mac OS X and Windows.

Cinema 4D Release19 Image Links
Cinema 4D Release 19 Information
New in Release 19 Videos
Pressroom

About MAXON

Headquartered in Friedrichsdorf, Germany, MAXON Computer is a developer of professional 3D modeling, painting, animation and rendering solutions. Its award-winning Cinema 4D and BodyPaint 3D software products have been used extensively to help create everything from stunning visual effects in top feature films, TV shows and commercials, cutting-edge game cinematics for AAA games, as well for medical illustration, architectural and industrial design applications. MAXON has offices in Germany, USA, United Kingdom, Canada, France, Japan and Singapore. MAXON products are available directly from the web site and its worldwide distribution channel. MAXON is part of the Nemetschek Group.

Additional information on MAXON can be obtained as follows:

Website: http://www.maxon.net

Facebook: https://www.facebook.com/maxon3d

Twitter: https://twitter.com/maxon3d

YouTube: https://www.youtube.com/user/MaxonC4D

LinkedIn: https://www.linkedin.com/company/791366

Google+: https://plus.google.com/+maxoncinema4d

Instagram: https://www.instagram.com/maxonc4d/

All trademarks contained herein are the property of their respective owners.

Contact information

MAXON
Jessica Wege
+49 6172 5906-643
press_de@maxon.net

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 16:25Tiedote

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the

IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 15:00Tiedote

IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman

PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 11:03Tiedote

PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate

Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 11:00Tiedote

Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The

Boehringer Ingelheim: Advancing anticoagulation care with new data at ESC Congress 201721.8.2017 10:08Tiedote

Boehringer Ingelheim today announced that it will present important new data on the treatment of patients with atrial fibrillation (AF) at the ESC Congress in Barcelona, Spain, 26-30 August 2017. In total, four abstracts have been accepted, investigating different aspects of AF patient treatment. The results of the RE-DUAL PCI™ trial have been selected for one of the Late Breaking Science sessions of the congress. The RE-DUAL PCI™ trial compared dual therapy with triple therapy after percutaneous coronary intervention (PCI) with stent placement in approximately 2,500 adults with atrial fibrillation. Patients were either treated with dabigatran etexilate (Pradaxa®) and a single antiplatelet agent or with the vitamin K antagonist (VKA) warfarin and two antiplatelets. The dabigatran doses investigated in this trial are the same doses which have already demonstrated effective stroke preven

Study Investigates Performance of Masimo PVi® As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery21.8.2017 09:00Tiedote

Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Firat University in Turkey evaluated the performance of Masimo PVi®, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during respiratory cycles, as the basis of a goal-directed fluid therapy (GDFT) protocol during laparoscopic bariatric surgery on mechanically-ventilated patients.1 In the study, Dr. Demirel and colleagues sought to evaluate whether using GDFT guided by PVi on morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) surgery might result in less intravenous fluid use without compromising outcomes. They enrolled 60 patients and divided them randomly into control and GDFT groups. The control group’s fluid levels were managed by standard fluid therapy, using mean arterial pressure (MAP) and

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme